CoChat

The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index; 28 of the 71 sources its claims cite were checked for support.

Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention

Open access

Abstract

Cardiovascular diseases represent the leading cause of death in the world and are subject to limitations in prevention strategies despite the use of very effective drugs. The concept of residual risk (RR) is intrinsically related to that of global risk of which it represents a very significant percentage. In the cardiovascular field, the term RR refers to the probability of incurring a major cardiovascular event, despite adequate control of the risk factors present in the individual patient. A significant portion of the RR in the cardiovascular field results from the underestimation of additional risk factors not subjected to adequate intervention such as, for example, triglyceride levels in patients treated for the presence of hypertension and/or hypercholesterolemia. The control of the RR therefore appears as an essential condition for the effective reduction of the global risk profile and is based on an integrated intervention that combines all the different prevention strategies derived from the available evidence and capable of interacting on the basis of a strengthening reciprocal between lifestyle and pharmacological and nutraceutical intervention methods.

Overview

CoChat Summary

TL;DR

This paper is a narrative review of residual cardiovascular risk, arguing that LDL-C lowering alone leaves important risk unexplained and highlighting remnant cholesterol, monocyte/HDL ratio, and several lipoprotein ratios as additional markers. It summarizes prior studies suggesting these markers improve risk stratification and may identify patients with ongoing risk despite statin therapy.

Key findings

  • Residual cardiovascular risk is defined here as the probability of a major cardiovascular event despite treatment according to standards of care, and the paper argues that classic risk calculators may underestimate risk in treated patients.
  • Remnant cholesterol is presented as an independent risk marker: in non-fasting populations, RC values > 43 mg/dL were associated with a 2–3 times greater risk of ischemic heart disease than values < 15 mg/dL, and a 1 mmol/L (39 mg/dL) increase in RC was associated with a 2.8-fold increase in coronary heart disease risk.
  • Monocyte/HDL ratio (MHR) is described as a marker of inflammation and cardiovascular risk; reported cut-offs included 12.1 for hemodynamically significant coronary stenosis, 30.1 for higher mortality/MACE risk in STEMI, and 17.5 for predicting 30-day mortality in stroke.
  • Lipoprotein ratios were reported to outperform single lipids in predicting risk; the paper cites CT/HDL-C values ≥ 5.5 and LDL/HDL-C > 5 as associated with increased coronary event risk, and TG/HDL-C > 4 as a strong independent predictor of coronary artery disease and microvascular dysfunction.

Methods

  • Narrative review article synthesizing prior epidemiological, clinical, and experimental studies on residual cardiovascular risk markers.
  • No new sample was collected by the authors; instead, the paper summarizes cited studies, including examples such as 301 angiography patients, 440 STEMI patients, 1170 STEMI patients, 2312 type 2 diabetes patients undergoing angioplasty, and a Danish population cohort of over 90,000 individuals followed for 22 years.
  • The main analysis is qualitative comparison of the prognostic value of remnant cholesterol, MHR, platelet/lymphocyte ratio, lipoprotein ratios, apoB, non-HDL cholesterol, and Lp(a) against conventional LDL-C-centered assessment.

Limitations

  • Not stated in the paper.
  • Evident from the text: this is a review, not an original study, so its conclusions depend on the quality and heterogeneity of the cited literature rather than a single unified dataset.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/jpm14050460

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Residual cardiovascular risk.
Figure 1 Residual cardiovascular risk.CC BY · PubMed Central

Verification

Claims the paper makes

23 Valid · 5 Not valid · 41 Not checked · 12 Own results and interpretations

41 more claims · 11 with their cited sources checked

Create a free account to see all 81 claims and to verify the 11 references still open.

See all claims — free account
  • It may state two separate claims as one. 26
  • Probably not a substantial claim. 14

Create a free account to see these claims.

Citations

Cites

Show all 48 references

Cited by

See all 12

Metadata

Authors
Sucato, V., Comparato, F., Ortello, A., Galassi, A. R., & Novo, G.
Affiliations
Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo (IT)
Corresponding author
Sucato, Vincenzo
Venue
Journal of Personalized Medicine
Publisher
MDPI AG
Published
2024-04-26
Volume
14
Issue
5
Pages
460
ISSN
2075-4426 (ISSN-L)
OpenAlex
W4395676315
Cited by
12
References
48
Citations by year
2026: 4 · 2025: 6 · 2024: 2
FWCI
1.32
Type
journal article
Language
en
Open access
Locations
  • Journal of Personalized Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • IRIS UniPA (University of Palermo) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Risk Factors
Keywords
residual cardiovascular risk, remnant cholesterol, monocyte/HDL ratio, lipoprotein ratios, cardiovascular disease prevention, triglycerides, hypercholesterolemia, hypertension, personalized prevention, lifestyle intervention, nutraceuticals, pharmacological interventions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention. https://app.cochat.ai/papers/10.3390/jpm14050460
The paper
Sucato, V., Comparato, F., Ortello, A., Galassi, A. R., & Novo, G. (2024). Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention. Journal of Personalized Medicine. https://doi.org/10.3390/jpm14050460

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.